Alnylam Pharmaceuticals Inc (ALNY)vsExelixis Inc (EXEL)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
EXEL
Exelixis Inc
$52.49
-0.24%
HEALTHCARE · Cap: $13.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 80% more annual revenue ($4.29B vs $2.38B). EXEL leads profitability with a 35.1% profit margin vs 12.6%. ALNY appears more attractively valued with a PEG of 0.48. EXEL earns a higher WallStSmart Score of 72/100 (B).
ALNY
Strong Buy65
out of 100
Grade: B-
EXEL
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Margin of Safety
+67.2%
Fair Value
$161.90
Current Price
$52.49
$109.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Every $100 of equity generates 43 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 41.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 35.1% and operating margin at 41.1%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Key Dynamics to Monitor
ALNY profiles as a growth stock while EXEL is a mature play — different risk/reward profiles.
EXEL carries more volatility with a beta of 0.43 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
EXEL generates stronger free cash flow (250M), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (72/100 vs 65/100), backed by strong 35.1% margins. ALNY offers better value entry with a 86.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?